Amphastar obtains FDA nod for generic Vasostrict
Generic Vasostrict is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
The Food and Drug Administration has cleared Amphastar’s generic vasopressin injection.
The medication, which is the generic of Par Sterile Products' Vasostrict, is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
[Read more: FDA gives Amphastar tentative OK for vasopressin injection]
Amphastar received a tentative nod from the FDA for vasopressin 20 units/ml, 1ml single-dose vial in December 2021.
[Read more: Amphastar obtains FDA OK for morphine sulfate injection]
The company expects to launch the product in the coming weeks.